This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering



QBiotics discovers and develops novel small molecule drug candidates from its proprietary EcoLogicTM phenotypic screening platform. Our lead oncology molecule, tigilanol tiglate, provides for single injection treatment against a broad range of solid tumors, currently in Phase II trials in patients with head and neck cancers and soft tissue sarcoma. Tigilanol tiglate has secured regulatory and commercial validation as a marketed veterinary product STELFONTA® for canine mast cell tumors, reporting a 75% Complete Response (CR) rate in a FDA pivotal canine trial. With more than 15,000 canine patients treated globally, STELFONTA® generates milestone payments and revenues in USA, UK, EU and Australia. QBiotics’ business model is to discover and develop novel therapeutics that have application in both veterinary and human markets, to proof of concept and then partner for late-stage development and commercialisation. Success in the veterinary programs validates QBiotics technology and de-risks human development, while generating early, non-diluting revenues. Follow on asset, EBC-1013 for treating debilitating stubborn wounds, is currently in early clinical development for acute wounds in horses, and Phase I set-up stage for venous leg ulcers in humans.